SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

ZOVIRAX FOR INJECTION

Registration number

of the mixture

Synonyms ZOVIRAX FOR INJECTION 500 MG * ZOVIRAX FOR INJECTION 1000 MG * ZOVIRAX IV FOR

INFUSION 250 MG * ZOVIRAX IV FOR INFUSION 500 MG * ACYCLOVIR SODIUM,

FORMULATED PRODUCT

Issue date 28-November-2013

Version number

Revision date 28-November-2013 Supersedes date 03-May-2013

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information None.

2.3. Other hazards Caution - Pharmaceutical agent.

See section 11 for additional information on health hazards.

Expected to be non-combustible.

No information is available about the potential of this product to produce adverse environmental

effects.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Material name: 70VIRAX FOR INJECTION SDS UK **General information**

CAS-No. / EC No. REACH Registration No. INDEX No. Chemical name **Notes**

ACYCLOVIR 5 - < 1059277-89-3

261-685-1

Classification: DSD: -

CLP: -

Other components below reportable levels 90.0 - 95.0

CLP: Regulation No. 1272/2008. DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance. PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

SECTION 4: First aid measures

General information Not available

4.1. Description of first aid measures

Inhalation If not breathing, give artificial respiration. If breathing is difficult, trained personnel should give

oxygen. Get medical attention immediately.

Skin contact Immediately flush with plenty of water for at least 15 minutes while removing contaminated clothing

and shoes. Remove and isolate contaminated clothing and shoes. Get medical attention if

symptoms occur.

Eye contact In the case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

Get medical attention if irritation develops and persists.

Ingestion Call a physician or poison control centre immediately. Only induce vomiting at the instruction of

> medical personnel. Never give anything by mouth to an unconsious person. If swallowed, rinse mouth with water (only if the person is conscious). Get medical attention if symptoms occur.

4.2. Most important symptoms and effects, both acute and

delayed

Not available.

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5: Firefighting measures

General fire hazards Expected to be non-combustible.

5.1. Extinguishing media

Suitable extinguishing

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

media

Unsuitable extinguishing

media

None known.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

procedures

In the event of fire, cool tanks with water spray.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency

personnel

Keep unnecessary personnel away. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

6.2. Environmental precautions Prevent further leakage or spillage if safe to do so.

6.3. Methods and material for containment and cleaning up

Material name: 70VIRAX FOR INJECTION

Stop the flow of material, if this is without risk. Following product recovery, flush area with water.

6.4. Reference to other

sections

For personal protection, see section 8. For waste disposal, see section 13.

110608 Version No.: 12 Revision date: 28-November-2013 Issue date: 28-November-2013

SECTION 7: Handling and storage

7.1. Precautions for safe

handling

Avoid prolonged exposure. Use care in handling/storage.

7.2. Conditions for safe storage, including any incompatibilities

Store in accordance with local/regional/national/international regulation. Store away from

incompatible materials (see Section 10 of the MSDS).

7.3. Specific end use(s) Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Туре	Value
ACYCLOVIR (CAS 59277-89-3)	8 HR TWA	5000 mcg/m3
,	OHC	1

Biological limit values No biological exposure limits noted for the ingredient(s).

Recommended monitoring

procedures

Follow standard monitoring procedures.

Derived No Effect Level (DNEL) Not available. Predicted no effect concentrations (PNECs)

Not available.

8.2. Exposure controls

Appropriate engineering

controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them. No special engineering controls are required. Local exhaust ventilation (LEV) is recommended. Only authorised personnel may enter the working area.

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment.

Eye/face protection Wear approved safety glasses with side shields or cover goggles if eye contact is possible. (eg.

EN 166)

Skin protection

- Hand protection Glove selection must take into account any solvents and other hazards present. Care must be

> exercised if insufficient data are available and further guidance should be sought from your local EHS department. The selection of gloves for a specific activity must be based on the material's properties and on possible permeation and degradation that may occur under the circumstances of use. Potential allergic reactions can occur with certain glove materials (e.g. Latex) and therefore these should be avoided. With respect to the above precautions select suitable chemical resistant

protective gloves (EN 374) with a protective index 6 (>480min permeation time).

- Other Wear appropriate chemical resistant clothing. (EN 14605 for splashes, EN ISO 13982 for dust)

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators. If respiratory protective equipment (RPE) is used, the type of RPE will depend upon air concentrations present, required protection factor as well as hazards, physical properties and warning properties of substances present. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline

compounds and toxic particles (eg. EN 14387).

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures An eye wash station should be available. Wear appropriate clothing to avoid skin contact. Follow

all local regulations if personal protective equipment (PPE) is used in the workplace.

Environmental exposure controls

GSK environmental hazard

category

Not available.

Hazard guidance and control recommendations

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid.

Form Freeze dried powder.

110608 Version No.: 12 Revision date: 28-November-2013 Issue date: 28-November-2013

Colour Not available. Odour Not available. **Odour threshold** Not available. Not available. pН Not available. Melting point/freezing point Not available.

Initial boiling point and boiling

range

Not available. Flash point Not available. **Evaporation rate** Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits Flammability limit - lower Not available.

(%)

Flammability limit - upper

(%)

Not available.

Not available. Vapour pressure Vapour density Not available Relative density Not available. Not available. Solubility(ies) Not available. Partition coefficient

(n-octanol/water)

Auto-ignition temperature Not available. **Decomposition temperature** Not available. **Viscosity** Not available. **Explosive properties** Not available.

Oxidizing properties Not available.

9.2. Other information No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoid Contact with incompatible materials.

10.5. Incompatible materials

None known.

10.6. Hazardous decomposition products Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Based on available data, the classification criteria are not met. Ingestion Based on available data, the classification criteria are not met. Inhalation Based on available data, the classification criteria are not met. Skin contact Based on available data, the classification criteria are not met. Eye contact

Not available. **Symptoms**

11.1. Information on toxicological effects

Based on available data, the classification criteria are not met. **Acute toxicity**

Components **Species Test results**

ACYCLOVIR (CAS 59277-89-3)

Acute Inhalation

LC50 Rat > 15.1 mg/l, 4 hours

Material name: ZOVIRAX FOR INJECTION

SDS UK 110608 Version No.: 12 Revision date: 28-November-2013 Issue date: 28-November-2013

Components **Species Test results**

Oral

LD50 Rat > 20 g/kg

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Based on available data, the classification criteria are not met.

Irritation Corrosion - Skin

ACYCLOVIR Acute dermal irritation, Tested at 5% in a cream; Irritation

> Index 0.02 Result: negative Species: Rabbit

Serious eye damage/eye

irritation Eye

Based on available data, the classification criteria are not met.

ACYCLOVIR Acute ocular irritation

Result: negative Species: Rabbit

Respiratory sensitisation Due to lack of data the classification is not possible.

Skin sensitisation Based on available data, the classification criteria are not met.

Sensitisation

ACYCLOVIR Method not specified Result: negative

Species: Guinea pig

Germ cell mutagenicity Based on available data, the classification criteria are not met. No data available to indicate

product or any components present at greater than 0.1% are mutagenic or genotoxic.

Germ cell mutagenicity

Mutagenicity

ACYCLOVIR Ames Assay Result: negative

C3H/T10 1/2 Cell Transformation Assay

Result: negative

Chromosomal Aberration Assay In Vitro, Positive response only with levels much above equivalent of human therapeutic

dose

Result: positive Species: Hamster

Chromosomal Aberration Assay In Vitro, human lymphocytes

Result: Equivocal

Cytogenetic Analysis In Vivo, bone marrow

Result: negative Species: Mouse

Mouse lymphoma cell (L5178Y TK) Assay

Result: positive

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. Based on

available data, the classification criteria are not met.

ACYCLOVIR 2 year bioassay

> Result: negative Species: Mouse 2 year bioassay Result: negative Species: Rat

IARC Monographs. Overall Evaluation of Carcinogenicity

ACYCLOVIR (CAS 59277-89-3) 3 Not classifiable as to carcinogenicity to humans.

Reproductive toxicity Based on available data, the classification criteria are not met.

Reproductive toxicity

Fertility effects - Males and females

ACYCLOVIR Subcutaneous injection

> Result: NOAEL = 25 mg/kg/day; LOAEL = 50 mg/kg/day (decreased implantation efficiency, no effect on litter size)

Species: Rat

Reproductivity

ACYCLOVIR Embryo-foetal development - Oral, sub-cutaneous

administration

Result: NOAEL = 50 mg/kg/day; no adverse foetal effects

Species: Rabbit

Material name: ZOVIRAX FOR INJECTION 110608 Version No.: 12 Revision date: 28-November-2013 Issue date: 28-November-2013 Reproductivity

ACYCLOVIR Embryo-foetal development - Oral, sub-cutaneous

administration

Result: NOAEL = 50 mg/kg/day; no adverse foetal effects

Test results

Species: Rat

Specific target organ toxicity -

single exposure

Due to lack of data the classification is not possible.

Species

Specific target organ toxicity -

repeated exposure

Based on available data, the classification criteria are not met.

Aspiration hazard Mixture versus substance Not available. Not available.

information

Components

Not available. Other information

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

•		•	
ACYCLOVIR (CAS 59277-89-	3)		
Aquatic			
Acute			
Activated Sludge Respiration	IC50	Residential sludge	> 100 mg/l, 3 hours, OECD 209
Algae	EC50	Green algae (Selenastrum capricornutum)	> 99 mg/l, 96 hours, Static test, OECD 201
Crustacea	EC50	Water flea (Daphnia magna)	> 93 mg/l, 48 hours, Static test, OECD 202
Fish	EC50	Fathead minnow (Juvenile Pimephales promelas)	> 95 mg/l, 96 hours, Static renewal test, OECD 203
Microtox	MIC	Aspergillus flavus	> 993 mg/l, 5 days
		Azotobacter chroococcum	> 993 mg/l, 5 days
		Chaetomium globosum	> 993 mg/l, 5 days
		Nostoc sp.	> 993 mg/l, 5 days
		Pseudomonas fluorescens	> 993 mg/l, 5 days
Chronic			
Crustacea	LOEC	Water flea (Ceriodaphnia dubia)	> 10 mg/l, 7 days, 7 day static renewal, EPA 1002
	NOEC	Water flea (Ceriodaphnia dubia)	10 mg/l, 7 days

^{*} Estimates for product may be based on additional component data not shown.

12.2. Persistence and

No data is available on the degradability of this product.

degradability

Persistence and degradability

Photolysis

Half-life (Photolysis-aqueous)

ACYCLOVIR 3.55 Hours Measured, pH 7 Buffer Solution

Hydrolysis

Half-life (Hydrolysis-neutral)

ACYCLOVIR > 1 years Measured

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

50 %, < 1 day Modified Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-ready)

ACYCLOVIR 0.7 %, 28 days Sturm test

12.3. Bioaccumulative potential No data available for this product.

Partition coefficient n-octanol/water (log Kow)

> **ACYCLOVIR** -1.2

12.4. Mobility in soil

Material name: ZOVIRAX FOR INJECTION

Adsorption

Sludge/biomass distribution coefficient - log Kd

ACYCLOVIR 2.33 - 2.37 Estimated

Soil/sediment sorption - log Koc

ACYCLOVIR 2.6 - 2.64 Measured

12.5. Results of PBT

and vPvB assessment

Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging

EU waste code

Empty containers should be taken to an approved waste handling site for recycling or disposal. The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Disposal methods/information

Collect and reclaim or dispose in sealed containers at licensed waste disposal site.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

Read safety instructions, SDS and emergency procedures before handling.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended Not listed.

Material name: 70VIRAX FOR INJECTION

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations Not available.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations Not available.

References **GSK Hazard Determination**

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

Revision information SECTION 8: Exposure controls/personal protection: - Other Training information Follow training instructions when handling this material.

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Material name: ZOVIRAX FOR INJECTION

SDS UK 110608 Version No.: 12 Revision date: 28-November-2013 Issue date: 28-November-2013